A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

A high-level overview of Protagonist Therapeutics, Inc. (PTGX) stock. View (PTGX) real-time stock price, chart, news, analysis, analyst reviews and more.